{
    "body": "What is the effect of Allopurinol on asphyxia in neonates?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16428356", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17162192", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22564301", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22102633", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9445490", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16778717", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12436031", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20167117"
    ], 
    "ideal_answer": [
        "Allopurinol was shown in a number of clinical trial to be safe and effective for treatment of neonatal asphyxia. Allopurinol  improves short-term and long-term clinical outcomes of neonatal asphyxia. Allopurinol should be administered as soon as possible. Postulated mechanism of allopurinol action in this setting is prevention of hypoxia-perfusion injury by reduction of free radical formation."
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001238", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001237", 
        "http://www.biosemantics.org/jochem#4273300", 
        "http://www.disease-ontology.org/api/metadata/DOID:11088", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007231", 
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000493"
    ], 
    "type": "summary", 
    "id": "515df1d4298dcd4e5100002b", 
    "snippets": [
        {
            "offsetInBeginSection": 1203, 
            "offsetInEndSection": 1473, 
            "text": "Potential neuroprotective strategies targeting different pathways leading to neuronal cell death in response to hypoxic-ischemic insult have been investigated: hypothermia, erythropoietin, iminobiotin, deferioxamine, magnesium, allopurinol, xenon, melatonin and statins.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22564301", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 138, 
            "offsetInEndSection": 260, 
            "text": "Allopurinol reduces the formation of free radicals, thereby potentially limiting the amount of hypoxia-reperfusion damage.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102633", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1458, 
            "offsetInEndSection": 1771, 
            "text": "There were no differences in long-term outcome between the allopurinol-treated infants and controls. However, subgroup analysis of the moderately asphyxiated group showed significantly less severe adverse outcome in the allopurinol-treated infants compared with controls (25% vs 65%; RR 0.40, 95%CI 0.17 to 0.94).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102633", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1785, 
            "offsetInEndSection": 1910, 
            "text": "The reported data may suggest a (neuro)protective effect of neonatal allopurinol treatment in moderately asphyxiated infants.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102633", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1225, 
            "offsetInEndSection": 1356, 
            "text": "The asphyxiated newborns treated with allopurinol had better neurologic and neurodevelopmental outcome at 12 or more months of age.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17162192", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 192, 
            "text": "In newborn infants, allopurinol is being tested as a free radical scavenger to prevent brain damage caused by reperfusion and oxygenation after perinatal hypoxia and ischemia (birth asphyxia).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16778717", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 92, 
            "text": "Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16428356", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 364, 
            "offsetInEndSection": 468, 
            "text": "The analysis showed an unaltered (high) mortality and morbidity in the infants treated with allopurinol.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16428356", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 482, 
            "offsetInEndSection": 596, 
            "text": "Allopurinol treatment started postnatally was too late to reduce the early reperfusion induced free radical surge.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16428356", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 323, 
            "offsetInEndSection": 432, 
            "text": "One randomized trial of allopurinol showed short-term benefits but was too small to test death or disability.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12436031", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1235, 
            "offsetInEndSection": 1279, 
            "text": "No toxic side effects of ALLO were detected.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/9445490", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 2087, 
            "offsetInEndSection": 2235, 
            "text": "This study suggests a beneficial effect of ALLO treatment on free radical formation, CBV, and electrical brain activity, without toxic side effects.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/9445490", 
            "endSection": "sections.0"
        }
    ]
}